{"id":42684,"date":"2023-05-03T14:56:57","date_gmt":"2023-05-03T18:56:57","guid":{"rendered":"https:\/\/www.sisinternational.com\/?page_id=42684"},"modified":"2026-05-05T16:33:09","modified_gmt":"2026-05-05T20:33:09","slug":"investigacion-de-mercado-de-productos-farmaceuticos","status":"publish","type":"page","link":"https:\/\/www.sisinternational.com\/es\/pericia\/investigacion-de-mercado-de-productos-farmaceuticos\/","title":{"rendered":"Pharmaceuticals Market Research | SIS International"},"content":{"rendered":"
\n

Investigaci\u00f3n de mercado farmac\u00e9utico<\/a><\/h1>\n
\"Investigaci\u00f3n<\/figure>\n<\/p>\n

Los productos farmac\u00e9uticos tambi\u00e9n se conocen como medicamentos o f\u00e1rmacos farmac\u00e9uticos. Utilizamos estas sustancias y compuestos para prevenir, diagnosticar, tratar o aliviar enfermedades. Abordan enfermedades y condiciones de salud tanto en humanos como en animales. Las empresas farmac\u00e9uticas desarrollan y fabrican estos medicamentos mediante investigaciones y pruebas exhaustivas. Las agencias gubernamentales los regulan por su seguridad, eficacia y calidad.<\/p>\n

Podemos clasificar los productos farmac\u00e9uticos en varias categor\u00edas seg\u00fan su finalidad. Tambi\u00e9n podemos ordenarlos por modo de acci\u00f3n, composici\u00f3n qu\u00edmica y v\u00eda de administraci\u00f3n. Los m\u00e1s comunes incluyen medicamentos recetados y de venta libre, vacunas, productos biol\u00f3gicos y medicamentos gen\u00e9ricos.<\/p>\n

Las agencias gubernamentales regulan los medicamentos recetados. Los pacientes s\u00f3lo pueden comprar estos medicamentos con receta v\u00e1lida. Esta receta debe provenir de un proveedor de atenci\u00f3n m\u00e9dica calificado. Un proveedor puede ser un m\u00e9dico, una enfermera especializada o un dentista. Los proveedores recetan estos medicamentos para tratar afecciones complejas o cr\u00f3nicas. Su uso requiere una cuidadosa supervisi\u00f3n m\u00e9dica.<\/p>\n

Tambi\u00e9n existen medicamentos de venta libre o sin receta. Los consumidores pueden comprarlos sin receta. Usan estos medicamentos para tratar dolencias o s\u00edntomas menores. Su uso generalmente se considera seguro sin necesidad de supervisi\u00f3n de un m\u00e9dico.<\/p>\n

Las vacunas son productos farmac\u00e9uticos que se utilizan para prevenir la propagaci\u00f3n de enfermedades infecciosas. Estimulan el sistema inmunol\u00f3gico del cuerpo para luchar contra pat\u00f3genos espec\u00edficos. Los proveedores de atenci\u00f3n m\u00e9dica administran vacunas mediante inyecci\u00f3n u v\u00eda oral. Son cruciales para prevenir la propagaci\u00f3n de enfermedades. Por ejemplo, previenen la influenza, el sarampi\u00f3n, la polio y el COVID-19.<\/p>\n

Los productos biol\u00f3gicos son productos farmac\u00e9uticos procedentes de organismos vivos o de sus componentes. Las prote\u00ednas, enzimas o anticuerpos son ejemplos de productos biol\u00f3gicos. Estos medicamentos suelen tratar afecciones complejas como c\u00e1ncer, enfermedades autoinmunes y trastornos gen\u00e9ticos.<\/p>\n

Los medicamentos gen\u00e9ricos son productos farmac\u00e9uticos con los mismos ingredientes activos que sus hom\u00f3logos de marca. Tambi\u00e9n tienen la misma forma farmac\u00e9utica, concentraci\u00f3n y v\u00eda de administraci\u00f3n. Sin embargo, generalmente se venden a un costo menor que los medicamentos de marca. Las agencias reguladoras aprueban los medicamentos gen\u00e9ricos. Pero primero, sus fabricantes deben demostrar la bioequivalencia con el medicamento de marca original.<\/p>\n

Pharmaceuticals play a critical role in modern healthcare<\/a>. They help to prevent, diagnose, and treat various diseases and conditions. They also improve the health and well-being of millions of people around the world.<\/p>\n

\u00bfPor qu\u00e9 son importantes los productos farmac\u00e9uticos?<\/h2>\n

Los productos farmac\u00e9uticos son esenciales por varias razones. En primer lugar, ayudan en el tratamiento de enfermedades y condiciones de salud. Son cruciales para aliviar los s\u00edntomas, curar infecciones y controlar enfermedades cr\u00f3nicas. Mejoran la calidad de vida de millones de personas en todo el mundo. La gente usa productos farmac\u00e9uticos para tratar dolencias cotidianas como alergias, tos y resfriados. Tambi\u00e9n los utilizan para enfermedades graves como c\u00e1ncer, enfermedades card\u00edacas y diabetes. Las drogas tambi\u00e9n pueden combatir enfermedades infecciosas como el VIH\/SIDA.<\/p>\n

Los productos farmac\u00e9uticos tambi\u00e9n contribuyen al avance de la investigaci\u00f3n y la innovaci\u00f3n m\u00e9dicas. Estos medicamentos son el resultado de extensos esfuerzos de investigaci\u00f3n y desarrollo por parte de las compa\u00f1\u00edas farmac\u00e9uticas. Las instituciones acad\u00e9micas y otras organizaciones de investigaci\u00f3n tambi\u00e9n contribuyen a los esfuerzos de I+D. Estos esfuerzos impulsan la innovaci\u00f3n m\u00e9dica. Permiten el descubrimiento y desarrollo de nuevos medicamentos, vacunas y terapias. La investigaci\u00f3n farmac\u00e9utica conduce al descubrimiento de nuevas opciones de tratamiento y formulaciones mejoradas. Tambi\u00e9n da como resultado una mejor comprensi\u00f3n de las enfermedades. Estos factores contribuyen a los avances en el conocimiento m\u00e9dico y la atenci\u00f3n al paciente.<\/p>\n

Los productos farmac\u00e9uticos son esenciales por su papel en la prevenci\u00f3n de enfermedades y la salud p\u00fablica. Desempe\u00f1an un papel crucial en la prevenci\u00f3n de la propagaci\u00f3n de enfermedades infecciosas. Por ejemplo, las vacunas son fundamentales para proteger a las poblaciones de las enfermedades. Fueron esenciales en la lucha contra enfermedades como el sarampi\u00f3n, la polio y la influenza. Tambi\u00e9n es f\u00e1cil recordar su papel en la pandemia de COVID-19. Las vacunas han sido fundamentales para erradicar o controlar muchas enfermedades mortales a lo largo de la historia. Son una piedra angular de los esfuerzos de salud p\u00fablica.<\/p>\n

Los productos farmac\u00e9uticos mejoran los resultados de los pacientes y la calidad de vida. Pueden aliviar los s\u00edntomas y ralentizar la progresi\u00f3n de la enfermedad. Tambi\u00e9n previenen complicaciones y reducen las tasas de hospitalizaci\u00f3n. Estos medicamentos permiten a los pacientes controlar enfermedades cr\u00f3nicas y recuperarse de enfermedades agudas. Por lo tanto, pueden llevar una vida m\u00e1s saludable. Los productos farmac\u00e9uticos tambi\u00e9n ayudan a reducir la carga de morbilidad en las personas, las familias y los sistemas sanitarios. Previenen la discapacidad, mejoran la productividad y reducen los costos de atenci\u00f3n m\u00e9dica a largo plazo.<\/p>\n

Otra raz\u00f3n por la que los productos farmac\u00e9uticos son esenciales es por su impacto econ\u00f3mico. Desempe\u00f1an un papel importante en la creaci\u00f3n de empleo. La industria farmac\u00e9utica contribuye a las econom\u00edas globales. Produce miles de millones de d\u00f3lares en ingresos y crea millones de puestos de trabajo en todo el mundo. Las empresas farmac\u00e9uticas invierten en investigaci\u00f3n y desarrollo, fabricaci\u00f3n y distribuci\u00f3n. Estas acciones apoyan el crecimiento econ\u00f3mico y fomentan la innovaci\u00f3n. Adem\u00e1s, la disponibilidad de productos farmac\u00e9uticos eficaces ayuda a las personas a mantenerse sanas y productivas. Contribuye al bienestar econ\u00f3mico de las comunidades y sociedades.<\/p>\n

Los productos farmac\u00e9uticos permiten avances en la atenci\u00f3n sanitaria y la medicina personalizada. Los productos farmac\u00e9uticos son una parte integral de los avances en la atenci\u00f3n m\u00e9dica. Estos avances incluyen la medicina personalizada, que adapta los tratamientos a las caracter\u00edsticas \u00fanicas de un individuo. Considera factores como la gen\u00e9tica, el estilo de vida y el historial m\u00e9dico. Este enfoque permite tratamientos m\u00e1s precisos y eficaces. Conduce a mejores resultados para los pacientes. Tambi\u00e9n reduce la necesidad de sistemas de prueba y error en la atenci\u00f3n sanitaria.<\/p>\n<\/div>\n

Pharmaceuticals Market Research: How Leading Manufacturers Win Launch and Access Decisions<\/h1>\n

Pharmaceuticals market research has shifted from descriptive reporting to evidence that directly shapes pricing, sequencing, and payer negotiations. The work that matters now happens earlier, deeper in the science, and closer to the prescriber.<\/p>\n

Commercial leaders at large manufacturers face a tighter calculus. Indication prioritization, HTA submission evidence, and payer value story development run in parallel rather than in stages. The firms moving fastest treat market research as the connective tissue across medical affairs, market access, and commercial strategy.<\/p>\n

What Pharmaceuticals Market Research Now Delivers<\/h2>\n

Pharmaceuticals market research is the structured collection of clinical, payer, prescriber, and patient evidence used to guide portfolio, launch, and access decisions across a drug’s lifecycle. It blends KOL mapping, patient journey mapping, real-world evidence synthesis, and competitive intelligence into a single decision input.<\/p>\n

The work that earns budget is no longer volume tracking. It is research that resolves a specific commercial question: which indication first, which comparator anchors the value story, where biosimilar entry compresses margin, and how formulary positioning shifts when a competitor reads out Phase 3 data.<\/p>\n

The Four Decisions Research Must Answer<\/h3>\n

Across the manufacturers that launch well, four questions recur. Indication sequencing. Payer evidence gaps. Prescriber adoption barriers. Competitive response timing. Research designed around these questions outperforms generic landscape studies on every measure leadership cares about.<\/p>\n

Why Launch Sequencing Has Become the Highest-Value Research Question<\/h2>\n

Launch sequencing decisions now carry more value than pricing decisions for many specialty assets. The reason is structural. A first indication sets the reference price, the payer reimbursement template, and the prescriber anchor for every follow-on indication. Get the first indication wrong and the asset spends its lifecycle correcting an early mispositioning.<\/p>\n

The strongest sequencing work combines payer advisory boards, structured prescriber interviews, and competitive intelligence on parallel pipelines. Manufacturers that invested in this discipline early, including Vertex in cystic fibrosis and Regeneron in ophthalmology, built sequencing playbooks that others now study.<\/p>\n

According to SIS International Research, indication prioritization studies that integrate payer willingness-to-pay testing with prescriber switching thresholds produce sequencing recommendations that hold up under HTA scrutiny in EU5 markets, where England’s NICE and Germany’s G-BA apply different evidence weights to the same dossier.<\/span><\/span><\/p>\n

How Real-World Evidence Reshapes the Payer Value Story<\/h2>\n

Payers in the United States, Germany, and France have moved from accepting trial data to demanding real-world evidence on adherence, total cost of care, and comparative effectiveness against standard of care. The payer value story now lives or dies on RWE quality.<\/p>\n

The manufacturers winning access conversations build RWE strategies before Phase 3 readout, not after. They identify the comparator data gaps payers will flag, commission claims database studies and chart reviews to fill them, and pressure-test the resulting value story with structured payer interviews across IDNs, regional plans, and national sickness funds.<\/p>\n

This matters because payer rejection rarely cites the pivotal trial. It cites the absence of evidence on the populations payers actually cover. Research that anticipates the gap closes it before submission.<\/p>\n

What KOL Mapping Looks Like When Done Right<\/h2>\n

KOL mapping has been diluted by vendors selling lists of names. Useful KOL mapping identifies which clinicians shape guideline language at ASCO, ASH, ESMO, and AHA, which sit on payer P&T committees, and which run the academic centers that anchor referral patterns for a given indication.<\/p>\n

The output is not a contact database. It is an influence map showing how a guideline change in one society propagates through formulary decisions, prescriber adoption, and patient access over the following 18 months. Manufacturers that map influence this way time their medical affairs engagement to the moments that matter.<\/p>\n

SIS International’s expert interview programs across oncology and rare disease have found that KOL influence concentrates more tightly than most commercial teams assume. In several therapeutic areas, fewer than 30 clinicians globally shape the language that determines reimbursement outcomes across G7 markets.<\/span><\/p>\n

The SIS Pharmaceuticals Research Decision Framework<\/h3>\n
\n\n\n\n\n\n\n\n\n\n
Decision<\/th>\nPrimary Method<\/th>\nEvidence Output<\/th>\n<\/tr>\n<\/thead>\n
Indication sequencing<\/td>\nPayer advisory boards plus prescriber interviews<\/td>\nWillingness-to-pay and switching thresholds<\/td>\n<\/tr>\n
Launch readiness<\/td>\nPatient journey mapping plus chart audits<\/td>\nDiagnosis-to-treatment friction map<\/td>\n<\/tr>\n
Payer value story<\/td>\nRWE synthesis plus structured payer interviews<\/td>\nEvidence gap closure plan<\/td>\n<\/tr>\n
Competitive response<\/td>\nPipeline intelligence plus KOL mapping<\/td>\nScenario-weighted launch calendar<\/td>\n<\/tr>\n
Lifecycle defense<\/td>\nBiosimilar competitive intelligence<\/td>\nMargin compression timeline<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/figure>\n

Source: SIS International Research<\/em><\/p>\n

Where Patient Journey Mapping Creates Commercial Lift<\/h2>\n

Patient journey mapping has matured from a marketing exercise into a commercial diagnostic. The strongest work identifies the specific point at which patients drop out of the diagnosis-to-treatment pathway and quantifies the revenue at stake.<\/p>\n

In specialty categories such as multiple sclerosis, IBD, and HER2-positive breast cancer, the gap between diagnosis and appropriate treatment can extend across multiple specialist visits. Each handoff is a leak point. Research that quantifies leak points by geography, payer type, and referral pattern produces the precise inputs medical affairs and field teams need to allocate effort.<\/p>\n

This is where ethnographic research and chart audits outperform survey data. Surveys capture what physicians say they do. Chart audits and observation capture what actually happens at the point of care.<\/p>\n

How Biosimilar and LOE Intelligence Protects Margin<\/h2>\n
\"Investigaci\u00f3n<\/figure>\n

Loss of exclusivity research has become a continuous discipline rather than a defensive project run in the year before patent expiry. Biosimilar competitive intelligence now starts five to seven years out, tracking development pipelines, manufacturing capacity, and payer policy signals across the United States, EU5, Japan, and emerging markets.<\/p>\n

Manufacturers that protect margin best run scenario models that link biosimilar entry probability to formulary tier movement, contracting strategy, and authorized generic decisions. The output is a quarter-by-quarter margin compression timeline that finance, market access, and commercial leadership can plan against.<\/p>\n

SIS International’s competitive intelligence engagements across biologics have documented a consistent pattern: the first biosimilar entrant captures meaningful share within twelve months when payer step-edits align with launch, and substantially less when contracting locks the originator into preferred tier status.<\/span><\/p>\n

What Separates the Strongest Pharmaceuticals Market Research Programs<\/h2>\n
\"Investigaci\u00f3n<\/figure>\n

The manufacturers extracting the most value from research share three habits. They commission research against named decisions, not topic areas. They integrate qualitative depth with quantitative validation rather than choosing between them. They treat international scope as essential, recognizing that a launch decision in the United States is incomplete without parallel evidence from EU5, Japan, China, and Brazil.<\/p>\n

Pharmaceuticals market research at this level requires fieldwork capacity in regulated markets, expert interview networks across therapeutic areas, and analytic teams fluent in HTA submission logic. SIS International Research has supported manufacturers across specialty pharmaceuticals, imaging agents, and emerging market entry with mixed-methods programs that integrate prescriber, payer, and patient evidence into single decision-grade deliverables.<\/p>\n

The Direction Pharmaceuticals Market Research Is Moving<\/h2>\n
\"Investigaci\u00f3n<\/figure>\n

Three shifts are reshaping the discipline. Research budgets are consolidating around fewer, deeper programs tied to launch and access milestones. RWE is moving from a payer requirement to a commercial input that shapes positioning. And pricing pressure across G7 markets is forcing earlier integration of HTA evidence planning into clinical development.<\/p>\n

The manufacturers that lead the next decade will be the ones that treat pharmaceuticals market research as commercial infrastructure rather than a vendor purchase. The evidence base they build now will determine which assets reach peak sales and which stall in access negotiations.<\/p>\n

Acerca de SIS Internacional<\/h2>\n

SIS Internacional<\/a> ofrece investigaci\u00f3n cuantitativa, cualitativa y estrat\u00e9gica. Proporcionamos datos, herramientas, estrategias, informes y conocimientos para la toma de decisiones. Tambi\u00e9n realizamos entrevistas, encuestas, grupos focales y otros m\u00e9todos y enfoques de investigaci\u00f3n de mercado. P\u00f3ngase en contacto con nosotros<\/a> para su pr\u00f3ximo proyecto de Investigaci\u00f3n de Mercado.<\/p>\n

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n<\/p>\n

\n

Related SIS Resources<\/h3>\n